A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis

Victoria M. Lim, Eric L. Maranda, Vivek Patel, Brian J. Simmons, Joaquin J Jimenez

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Prurigo nodularis (PN) is a chronic dermatoses characterized by intensely pruritic, excoriated, or lichenified nodules. Standard therapy includes corticosteroids, antihistamines, and phototherapy; however, treatment results are often inadequate or transient. Thalidomide and its analogue lenalidomide are immunomodulatory drugs that have successfully been used to treat refractory cases of PN. A systematic review was performed evaluating the use of thalidomide and lenalidomide for PN. Eighteen articles were included in this study in which a total of 106 patients were evaluated, of whom 76 (71.7%) had moderate to significant improvement of PN with the use of thalidomide, lenalidomide, or both. Patients given thalidomide were treated with doses of 50–300 mg daily for 1–142 months, with the majority being treated for less than 1 year. Patients treated with lenalidomide were given a daily dose of 5–10 mg from 3 to 24 months. The most common side effects observed were sedation, gastrointestinal symptoms, and transient peripheral neuropathy. While thalidomide and lenalidomide are drugs that have shown promising results in these studies, caution should be taken in prescribing these medications and patients should be informed about the potential side effects. As such, large-scale randomized controlled trials with long-term follow-up are needed to determine appropriate dosing, efficacy, and toxicity profiles.

Original languageEnglish (US)
Pages (from-to)397-411
Number of pages15
JournalDermatology and Therapy
Volume6
Issue number3
DOIs
StatePublished - Sep 1 2016

Fingerprint

Prurigo
Thalidomide
Therapeutics
Phototherapy
Histamine Antagonists
Peripheral Nervous System Diseases
Skin Diseases
Pharmaceutical Preparations
Adrenal Cortex Hormones
Randomized Controlled Trials
lenalidomide

Keywords

  • Lenalidomide
  • Nodular prurigo
  • Prurigo nodularis
  • Pruritus
  • Thalidomide
  • Treatment

ASJC Scopus subject areas

  • Dermatology

Cite this

A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis. / Lim, Victoria M.; Maranda, Eric L.; Patel, Vivek; Simmons, Brian J.; Jimenez, Joaquin J.

In: Dermatology and Therapy, Vol. 6, No. 3, 01.09.2016, p. 397-411.

Research output: Contribution to journalReview article

Lim, Victoria M. ; Maranda, Eric L. ; Patel, Vivek ; Simmons, Brian J. ; Jimenez, Joaquin J. / A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis. In: Dermatology and Therapy. 2016 ; Vol. 6, No. 3. pp. 397-411.
@article{37fd7ac59a7b48d6a586c7b8fab9be7d,
title = "A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis",
abstract = "Prurigo nodularis (PN) is a chronic dermatoses characterized by intensely pruritic, excoriated, or lichenified nodules. Standard therapy includes corticosteroids, antihistamines, and phototherapy; however, treatment results are often inadequate or transient. Thalidomide and its analogue lenalidomide are immunomodulatory drugs that have successfully been used to treat refractory cases of PN. A systematic review was performed evaluating the use of thalidomide and lenalidomide for PN. Eighteen articles were included in this study in which a total of 106 patients were evaluated, of whom 76 (71.7{\%}) had moderate to significant improvement of PN with the use of thalidomide, lenalidomide, or both. Patients given thalidomide were treated with doses of 50–300 mg daily for 1–142 months, with the majority being treated for less than 1 year. Patients treated with lenalidomide were given a daily dose of 5–10 mg from 3 to 24 months. The most common side effects observed were sedation, gastrointestinal symptoms, and transient peripheral neuropathy. While thalidomide and lenalidomide are drugs that have shown promising results in these studies, caution should be taken in prescribing these medications and patients should be informed about the potential side effects. As such, large-scale randomized controlled trials with long-term follow-up are needed to determine appropriate dosing, efficacy, and toxicity profiles.",
keywords = "Lenalidomide, Nodular prurigo, Prurigo nodularis, Pruritus, Thalidomide, Treatment",
author = "Lim, {Victoria M.} and Maranda, {Eric L.} and Vivek Patel and Simmons, {Brian J.} and Jimenez, {Joaquin J}",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s13555-016-0122-9",
language = "English (US)",
volume = "6",
pages = "397--411",
journal = "Dermatology and Therapy",
issn = "2190-9172",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis

AU - Lim, Victoria M.

AU - Maranda, Eric L.

AU - Patel, Vivek

AU - Simmons, Brian J.

AU - Jimenez, Joaquin J

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Prurigo nodularis (PN) is a chronic dermatoses characterized by intensely pruritic, excoriated, or lichenified nodules. Standard therapy includes corticosteroids, antihistamines, and phototherapy; however, treatment results are often inadequate or transient. Thalidomide and its analogue lenalidomide are immunomodulatory drugs that have successfully been used to treat refractory cases of PN. A systematic review was performed evaluating the use of thalidomide and lenalidomide for PN. Eighteen articles were included in this study in which a total of 106 patients were evaluated, of whom 76 (71.7%) had moderate to significant improvement of PN with the use of thalidomide, lenalidomide, or both. Patients given thalidomide were treated with doses of 50–300 mg daily for 1–142 months, with the majority being treated for less than 1 year. Patients treated with lenalidomide were given a daily dose of 5–10 mg from 3 to 24 months. The most common side effects observed were sedation, gastrointestinal symptoms, and transient peripheral neuropathy. While thalidomide and lenalidomide are drugs that have shown promising results in these studies, caution should be taken in prescribing these medications and patients should be informed about the potential side effects. As such, large-scale randomized controlled trials with long-term follow-up are needed to determine appropriate dosing, efficacy, and toxicity profiles.

AB - Prurigo nodularis (PN) is a chronic dermatoses characterized by intensely pruritic, excoriated, or lichenified nodules. Standard therapy includes corticosteroids, antihistamines, and phototherapy; however, treatment results are often inadequate or transient. Thalidomide and its analogue lenalidomide are immunomodulatory drugs that have successfully been used to treat refractory cases of PN. A systematic review was performed evaluating the use of thalidomide and lenalidomide for PN. Eighteen articles were included in this study in which a total of 106 patients were evaluated, of whom 76 (71.7%) had moderate to significant improvement of PN with the use of thalidomide, lenalidomide, or both. Patients given thalidomide were treated with doses of 50–300 mg daily for 1–142 months, with the majority being treated for less than 1 year. Patients treated with lenalidomide were given a daily dose of 5–10 mg from 3 to 24 months. The most common side effects observed were sedation, gastrointestinal symptoms, and transient peripheral neuropathy. While thalidomide and lenalidomide are drugs that have shown promising results in these studies, caution should be taken in prescribing these medications and patients should be informed about the potential side effects. As such, large-scale randomized controlled trials with long-term follow-up are needed to determine appropriate dosing, efficacy, and toxicity profiles.

KW - Lenalidomide

KW - Nodular prurigo

KW - Prurigo nodularis

KW - Pruritus

KW - Thalidomide

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84982854155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982854155&partnerID=8YFLogxK

U2 - 10.1007/s13555-016-0122-9

DO - 10.1007/s13555-016-0122-9

M3 - Review article

AN - SCOPUS:84982854155

VL - 6

SP - 397

EP - 411

JO - Dermatology and Therapy

JF - Dermatology and Therapy

SN - 2190-9172

IS - 3

ER -